Dasatinib in Advanced Squamous Cell Lung Cancer

NCT01491633 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Safety issues/concerns per DF/HCC PI

Conditions

Squamous Cell Lung Cancer

Interventions

DRUG: Dasatinib

Sponsor

Dana-Farber Cancer Institute